Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Blood

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
Blood|November 20, 2008
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signalingMarc S Raab, Iris Breitkreutz, Giovanni Tonon, et al.
Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
Blood|July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genesK Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
Blood|November 20, 2008
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signalingMarc S Raab, Iris Breitkreutz, Giovanni Tonon, et al.
Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
Blood|July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genesK Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Pageof 2